1cP-LSD: Complete Prodrug Evidence, Toxicology Gaps & Safety Monograph

1cP-LSD: Complete Prodrug Evidence, Toxicology Gaps & Safety Monograph

Evidence warning: 1cP-LSD has strong analytical evidence and a convincing LSD-prodrug mechanism, but direct controlled human safety data remain extremely limited. This page does not convert LSD evidence into a 1cP-LSD dose chart.

Emergency psychedelic toxicity: Seizure, collapse, dangerous agitation/confusion, severe chest pain, extreme overheating, prolonged psychosis, or behavior that creates immediate risk of serious injury after an unknown psychedelic requires urgent medical assessment.

Quick answer

1cP-LSD is 1-cyclopropanoyl-LSD, an N1-acylated lysergamide designer drug that appears to function as a prodrug of LSD.

The best evidence is chemical and mechanistic:

• it has been identified in real blotter products;
• incubation with human serum produces LSD;
• preclinical behavioral testing shows psychedelic-like serotonergic activity;
• analytical methods can distinguish it when designed correctly.

What science still lacks is just as important:

• controlled human pharmacokinetics;
• controlled human dose-response;
• prospective cardiovascular monitoring;
• rare-adverse-event incidence;
• a validated human half-life;
• long-term safety.

Identity

History and market emergence

1cP-LSD is part of the modern N1-acyl lysergamide wave.

Unlike LSD itself, several N1-acyl derivatives were created or commercialized specifically within the research-chemical era.

1cP-LSD appeared after compounds such as:

• 1P-LSD;
• ALD-52;
• 1B-LSD.

Its emergence illustrates a recurring NPS strategy: small structural modification of a known psychedelic while retaining the possibility of conversion to the parent active compound.

What “prodrug of LSD” actually means

A prodrug is a substance that can be transformed into an active drug in the body.

In the 2020 Brandt study, 1cP-LSD incubated with human serum produced LSD.

That provides direct biochemical evidence supporting hydrolysis/deacylation.

What it does not prove

Human-serum incubation does not establish:

• the exact in-vivo conversion rate;
• the fraction converted in every person;
• the time course;
• a dose-equivalence ratio.

The study authors themselves noted that whole-body conversion could differ from serum-only experiments.

Preclinical psychedelic activity

1cP-LSD produced psychedelic-like behavioral activity in mice in a 5-HT2A-linked head-twitch model.

This supports the conclusion that the compound, its LSD metabolite, or both can produce serotonergic psychedelic activity.

Animal behavioral potency cannot be converted into a human recreational dose.

Relationship to LSD

1cP-LSD likely shares much of its ultimate pharmacology with LSD if it is efficiently converted in vivo.

But “likely LSD prodrug” is not the same as “identical to LSD in every clinical variable.”

Possible differences could include:

• absorption;
• conversion rate;
• onset kinetics;
• peak exposure;
• metabolite pattern;
• interindividual variability.

Those have not been mapped in controlled human trials.

Human evidence: the major gap

The peer-reviewed literature used for this monograph does not provide a robust controlled human 1cP-LSD trial.

Therefore claims about:

• onset;
• duration;
• subjective intensity;
• cardiovascular changes;
• comparative potency;
• “cleaner” or “easier” effects

should not be presented as established clinical facts.

Community reports can identify questions; they do not answer them scientifically.

Acute psychedelic risks

Direct 1cP-LSD incidence data are lacking.

Based on LSD/serotonergic-psychedelic class evidence, clinically relevant concerns include:

• panic/anxiety;
• confusion;
• impaired judgment;
• dangerous behavior;
• accidents;
• acute psychotic or manic reactions in susceptible people;
• prolonged perceptual symptoms in a minority of psychedelic users.

These are class-level concerns, not measured 1cP-LSD rates.

Cardiovascular effects

LSD can increase heart rate and blood pressure under controlled conditions.

Because 1cP-LSD appears to generate LSD, similar autonomic effects are plausible.

But no controlled 1cP-LSD study establishes:

• expected blood-pressure change;
• arrhythmia risk;
• a cardiovascular safety threshold.

Seizures and severe toxicity

Seizures are not a defining common effect of classic lysergamides, but severe events can occur with psychedelics, mixed exposures, underlying seizure vulnerability, or misidentified products.

For 1cP-LSD specifically, incidence is not known.

A product sold as “1cP-LSD” may also be chemically something else.

Fatalities: what is and is not established

This review did not identify a well-documented analytically confirmed 1cP-LSD-only fatality series in the peer-reviewed evidence used here.

That absence should not be translated into “1cP-LSD cannot be fatal.”

Several limitations prevent that conclusion:

• direct human exposure data are sparse;
• novel lysergamides are not included in many routine toxicology panels;
• 1cP-LSD can generate LSD biologically, complicating source attribution;
• blotters sold under one lysergamide name can contain another substance;
• fatal psychedelic events can occur indirectly through trauma, behavioral disturbance, co-drugs, hyperthermia, seizure, or underlying medical vulnerability.

Therefore the evidence status is fatality risk not quantified / isolated 1cP-LSD lethality not established, rather than treating an evidence gap as evidence of safety.

Product identity and blotter evidence

Japanese researchers identified 1cP-LSD in paper-sheet/blotter products distributed as designer drugs.

That confirms real commercial exposure.

It does not mean every blotter sold under the name is authentic.

Blotter appearance cannot distinguish:

• 1cP-LSD;
• LSD;
• another N1-acyl lysergamide;
• an NBOMe/NBOH compound;
• another psychedelic.

Analytical artifact: GC-induced deacylation

The 2020 analytical study found that gas-chromatographic analysis could generate degradation/deacylation products.

This matters because a laboratory can create an LSD-related signal during analysis if the method thermally alters the parent drug.

Forensic rule

A high-quality identification should rely on:

• orthogonal analytical methods;
• liquid-chromatography approaches when useful;
• authentic reference material;
• awareness of GC-induced degradation.

Metabolism

The strongest direct metabolic evidence is hydrolysis to LSD.

A complete controlled human metabolite map for 1cP-LSD is not established.

Related N1-acyl lysergamides commonly undergo:

• N1-deacylation;
• hydroxylation;
• N-dealkylation;
• further oxidative/conjugative metabolism.

Those related-drug pathways are context, not a complete 1cP-LSD human map.

Pharmacokinetics

No controlled human trial establishes a universal 1cP-LSD:

• bioavailability;
• time to peak;
• half-life;
• conversion rate to LSD;
• clearance;
• concentration-effect relationship.

Internet duration estimates should therefore not be treated as pharmacokinetic measurements.

Drug testing

Routine screens

Routine workplace/emergency immunoassays are not designed to specifically identify 1cP-LSD.

LSD itself is also absent from many routine panels.

Definitive testing

Identification may require:

• LC-MS/MS;
• LC-HRMS/QTOF;
• validated lysergamide methods;
• reference standards.

Analytical interpretation must account for conversion/degradation artifacts.

Tolerance

Classic serotonergic psychedelics can produce rapid pharmacodynamic tolerance through receptor adaptation.

Because 1cP-LSD appears to act through LSD-like serotonergic mechanisms, tolerance is biologically plausible.

However, no controlled human study establishes:

• exact onset;
• magnitude;
• cross-tolerance with LSD/psilocybin/AL-LAD.

Tolerance should not be used as a basis for escalating exposure.

Physical dependence and withdrawal

A classic physical-dependence syndrome comparable with opioids, alcohol, or benzodiazepines is not established for 1cP-LSD.

No validated withdrawal timeline exists.

This does not mean use cannot become harmful through:

• repeated risky behavior;
• psychiatric destabilization;
• compulsive experimentation;
• exposure to mislabeled products.

Substance-use-disorder context

Classic psychedelics generally show lower compulsive reinforcement than stimulants/opioids.

But 1cP-LSD-specific epidemiology is absent.

People whose psychedelic use is causing repeated harm can still benefit from substance-use and mental-health care.

Interactions

There are no controlled 1cP-LSD interaction trials.

Potential concern includes:

• serotonergic drugs;
• monoamine oxidase inhibitors;
• stimulants;
• substances increasing cardiovascular stress;
• drugs that impair judgment during a psychedelic state.

An interaction table cannot establish that a combination is safe.

Treatment and support

There is no 1cP-LSD-specific antidote.

Severe acute psychedelic reactions are treated according to the clinical problem:

• safety from injury;
• agitation;
• seizure;
• hyperthermia;
• cardiovascular instability;
• psychosis.

Persistent psychiatric symptoms warrant professional evaluation.

Forensic interpretation

Detection of LSD does not automatically prove only LSD was consumed

If 1cP-LSD is converted in vivo, LSD may appear as a downstream analyte.

Analytical degradation matters

GC-induced conversion can create additional ambiguity.

Product label is not proof

A blotter sold as 1cP-LSD requires chemical confirmation.

Special populations

No controlled 1cP-LSD safety studies establish risk in:

• pregnancy/breastfeeding;
• adolescents;
• older adults;
• cardiovascular disease;
• seizure disorders;
• bipolar disorder;
• psychotic disorders;
• significant liver disease.

Psychosis/mania vulnerability is a particularly important class-level concern with serotonergic psychedelics.

Legal status — dated October 2, 2026

This review does not identify a U.S. federal Schedule I listing specifically naming 1cP-LSD in the primary DEA schedule sources used here.

That is not a statement that sale or possession is lawful.

Potential legal frameworks include:

• federal analogue law depending on facts;
• state-specific controlled-substance or analogue laws;
• differing international controls.

Legal status should be checked by exact molecule, jurisdiction, intended use, and date.

Myths and misconceptions

“1cP-LSD is proven identical to LSD in humans.”
No. Prodrug evidence is strong, but controlled human comparative trials are lacking.

“If serum makes LSD, the dose conversion is obvious.”
False. Conversion rate and exposure kinetics matter.

“Blotter appearance proves identity.”
False.

“An LSD signal on GC-MS always proves LSD was originally present.”
Not necessarily; analytical deacylation can complicate interpretation.

“No withdrawal syndrome means no meaningful risk.”
False. Acute psychiatric, behavioral, and mislabeling risks remain.

Evidence ledger

Related evidence

• 1P-LSD
• AL-LAD
• 25I-NBOMe
• RC psychedelics evidence hub
• Substance Use, Dependence & Harm Reduction hub

Bottom line

1cP-LSD is one of the clearest examples of a research chemical where mechanism is much better established than human clinical safety.

We know it is a real marketed lysergamide and that human serum converts it to LSD.

We do not have the controlled human evidence needed to turn that fact into a precise potency, half-life, or safety claim.

The masterclass version therefore keeps the prodrug evidence strong—and the human evidence gap equally visible.